Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy

被引：11
作者：
Montagnon, Carmen M. [1 ]
Lehman, Julia S. [1 ,2 ]
Murrell, Dedee F. [3 ]
Camilleri, Michael J. [1 ,2 ]
Tolkachjov, Stanislav N. [4 ]
机构：
[1] Mayo Clin, Dept Dermatol, Rochester, MN USA
[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[3] Univ New South Wales, St George Hosp, Dept Dermatol, Sydney, NSW, Australia
[4] Epiphany Dermatol, Dallas, TX 75019 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 84卷 / 06期
关键词：
azathioprine; dapsone; intraepithelial autoimmune bullous dermatoses; IVIG; mycophenolate mofetil; pemphigus erythematosus; pemphigus foliaceus; pemphigus herpetiformis; paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome; Pemphigus Disease Activity Index; pemphigus vulgaris; rituximab; INTRAVENOUS IMMUNOGLOBULIN THERAPY; DISORDER INTENSITY SCORE; SEVERE PARANEOPLASTIC PEMPHIGUS; CYCLOPHOSPHAMIDE PULSE THERAPY; GLUCOCORTICOID-SPARING AGENT; LINKED-IMMUNOSORBENT-ASSAY; MYCOPHENOLATE-MOFETIL; ADJUVANT THERAPY; IMMUNOSUPPRESSIVE AGENTS; PLASMA-EXCHANGE;
D O I：
10.1016/j.jaad.2021.02.073
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Intraepithelial autoimmune blistering dermatoses are a rare group of skin disorders characterized by disruptions of inter-keratinocyte connections within the epidermis through the action of autoantibodies. The second article in this continuing medical education series presents validated disease activity scoring systems, serologic parameters of disease, treatments, and clinical trials for pemphigus and its subtypes.
引用
收藏
页码：1523 / 1537
页数：15
相关论文
共 154 条
[51]   A critical role of surgery in the treatment for paraneoplastic pemphigus caused by localized Castleman's disease [J].
Fang, Yujiang ;
Zhao, Lei ;
Yan, Feng ;
Cui, Xijun ;
Xia, Yue ;
Duren, Alicia .
MEDICAL ONCOLOGY, 2010, 27 (03) :907-911
[52]   A Pilot Study of Etanercept Treatment for Pemphigus Vulgaris [J].
Fiorentino, David F. ;
Garcia, Miki S. ;
Rehmus, Wingfield ;
Kimball, Alexa Boer .
ARCHIVES OF DERMATOLOGY, 2011, 147 (01) :117-118
[53]   Current Management Strategies in Paraneoplastic Pemphigus (Paraneoplastic Autoimmune Multiorgan Syndrome) [J].
Frew, John W. ;
Murrell, Dedee F. .
DERMATOLOGIC CLINICS, 2011, 29 (04) :607-+
[54]  
Gaspar Z S, 1996, Australas J Dermatol, V37, P93, DOI 10.1111/j.1440-0960.1996.tb01013.x
[55]   Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A [J].
Gergely, L ;
Váróczy, L ;
Vadász, G ;
Remenyik, É ;
Illés, A .
ACTA HAEMATOLOGICA, 2003, 109 (04) :202-205
[56]   Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis [J].
Gonzalez Santiago, Tania M. ;
Wetter, David A. ;
Kalaaji, Amer N. ;
Limper, Andrew H. ;
Lehman, Julia S. .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2016, 55 (08) :823-830
[57]   Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs [J].
Grando, Sergei A. .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2019, 58 (01) :114-125
[58]   Pemphigus foliaceus treated with etanercept [J].
Gubinelli, Emanuela ;
Bergamo, Fabio ;
Didona, Biagio ;
Annessi, Giorgio ;
Atzori, Francesco ;
Raskovic, Desanka .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (06) :1107-1108
[59]   Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb™ adsorber [J].
Guenther, Claudia ;
Laske, Joerg ;
Frind, Antje ;
Julius, Ulrich ;
Pfeiffer, Christiane .
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2008, 6 (08) :661-663
[60]   Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid [J].
Guercan, H. M. ;
Ahmed, A. Razzaque .
BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 (04) :723-731
12345678910